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Abstract
Background: RNA-Seq allows a theoretically unbiased analysis of both genome-wide transcription levels and
mutation status of a tumor. Using this technique we sought to identify novel candidate therapeutic targets
expressed in epithelial ovarian cancer (EOC).
Methods: Specifically, we sought candidate invasion/migration targets based on expression levels across all
tumors, novelty of expression in EOC, and known function. RNA-Seq analysis revealed the high expression of
CD151, a transmembrane protein, across all stages of EOC. Expression was confirmed at both the mRNA and
protein levels using RT-PCR and immunohistochemical staining, respectively.
Results: In both EOC tumors and normal ovarian surface epithelial cells we demonstrated CD151 to be localized to
the membrane and cell-cell junctions in patient-derived and established EOC cell lines. We next evaluated its role
in EOC dissemination using two ovarian cancer-derived cell lines with differential levels of CD151 expression.
Targeted antibody-mediated and siRNA inhibition or loss of CD151 in SKOV3 and OVCAR5 cell lines effectively
inhibited their migration and invasion.
Conclusion: Taken together, these findings provide the first proof-of-principle demonstration for a next generation
sequencing approach to identifying candidate therapeutic targets and reveal CD151 to play a role in EOC
dissemination.
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Background
Epithelial ovarian cancer (EOC) is the most common
cause of gynecologic cancer death and the fifth most
lethal cancer among women [1]. Despite a relatively low
occurrence rate (1 in 72) compared to other female can-
cers, the low 5-year survival rate of ~40% translates to
greater than 14,000 yearly deaths from ovarian cancer in
the United States [1]. One main contributor to the low
survival rate is the late stage at which EOC is usually
detected: upwards of 80% of EOC is discovered after
localized spread. When detected early, the EOC 5-year
survival rate is ~90% [2].
Beyond earlier diagnosis and detection, the identifica-
tion of novel therapeutic targets or approaches to over-
come chemoresistance is necessary to treat late stage or
recurrent disease that will occur even with more sensi-
tive and specific screening and detection methods. Since
the introduction of platinum-based drugs as first line
chemotherapy in the early 1980’s followed by the addi-
tion of taxane containing agents in the mid-1990’s, there
has been little change to the first line treatment of EOC
[3]. Novel administration methods, such as intraperito-
neal therapy, and dosing, such as dose-dense taxol, have
yielded slight improvements in progression-free survival
and overall survival [3]. Molecularly targeted therapies
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some promise but large conclusive trials have not been
completed [3]. Therefore, the need for new targets and
drugs remains high [1].
Next Generation Sequencing technology is now allowing
for the thorough and unbiased profiling of a number of
cancer genomes and transcriptomes [4-7]. Analysis of
mutational profiles, copy number variations, and expression
profiles have yielded insights into commonly affected genes
and pathways important for carcinogenesis in a number of
cancers including melanoma, pancreatic, lung, and breast
cancers [4-7]. Theoretically, by applying RNA-Seq technol-
ogy to ovarian cancers relevant pathways and molecules for
therapeutic intervention should be identifiable.
CD151 is an integral membrane protein and member of
the tetraspanin family. It associates with integrins and
other transmembrane proteins tetraspanin-enriched micro-
domains, thereby playing a role in cell-matrix or cell- cell
attachment [8,9]. Migration signaling pathways including
PI3K, FAK, and Rho/Src mediate cell behavior in response
to CD151 interactions [10-18]. Functionally, a CD151-tar-
geting antibody was shown to inhibit cell migration in an
in vivo breast cancer xenograft model and contain breast
cancer cells within a single contiguous tumor [19].
Using a highly clinically annotated sample set of EOC,
representing both early and late stage tumors, we inter-
rogated global expression patterns by RNA-Seq. We
identified the transmembrane protein CD151 as being
overexpressed in all tumor samples and then demon-
strated it to be a potential target to inhibit metastasis
and dissemination of ovarian cancer.
Methods
Patients and Specimen Collection
EOC tumor samples and ascites cells were collected
from MSSM and San Gerardo Hospital patients at the
time of surgery under their respective IRB-approved
protocols, as previously described [20]. Samples were
divided in the operating room and a portion sent for
pathology confirmation and staging. A portion was flash
frozen for subsequent RNA and protein analysis, and
another portion used for generating patient-derived cell
lines. For the RNA-Seq “discovery set”, 16 papillary
serous tumor samples representative of all stages of
the disease (3 stage I/II, 8 stage III, 1 stage IV, 2
peritoneal metastatic lesions, and 2 recurrent
tumors) and two borderline serous tumors were col-
lected and analyzed. An additional set of 25 tumors (6
stage I/II, 7 stage III/IV, 8 peritoneal metastatic lesions,
and 4 recurrent tumors) were used as a “validation set”.
RNA extraction
RNA was extracted from frozen tissue using QIAzol
according to manufacturer’s instructions (Qiagen,
Valencia, California). Briefly, tissue was homogenized in
QIAzol on ice. Chloroform was added, mixed and cen-
trifuged to allow for separation and removal of the aqu-
eous layer. RNA was precipitated in isopropanol
overnight at -20°C. The suspension was centrifuged to
pellet the RNA, washed with 75% ethanol and then
resuspended in RNAase-free water. RNA integrity num-
bers (RINs) were analyzed using the Agilent Bioanalyzer
a n do n l yR N Aw i t haR I No f>8 . 0w a ss u b m i t t e df o r
next-generation sequencing.
RNA-Seq
Epithelial ovarian cancer transcriptomes were prepared
for paired-end sequencing on the Illumina GAII plat-
form using the manufacturer’s protocols and with a sec-
ond size selection step to reduce ligation artifacts. Reads
were aligned using Eland32 (provided with the Illumina
sequencing platform). Expression levels were quantified
by running ERANGE v. 3.0.2. [21]. For each gene,
ERANGE reported the number of mapped reads per
kilobase of exon per million mapped reads (RPKM).
Quantitative Real-time Reverse Transcription PCR
RNA-Seq data was confirmed by quantitative real-time
PCR. One microgram of RNA was reverse transcribed
to cDNA using the BioRad Iscript system (Biorad, Her-
cules, California). Quantitative real-time PCR was per-
formed on an ABI PRISM 7900 HT sequence detection
system (Applied Biosystems, Carlsbad, California). Cycle
number values were normalized against two housekeep-
ing genes, B2 M and GAPDH. Data shown is the aver-
age of three separate experiments, each performed in
triplicate. The CD151 primers used were CD151 Fwd:
5’- AGACAGCTGCTGCAAGAC-3’ and CD151 Rev: 5’-
TGGATGAAGGTCTCCAACT-3’.
Immunohistochemistry and Fluorescent
Immunocytochemistry
Four-micrometer thick tumor sections were stained with
a-CD151 antibody (Cat # NCL-CD151, Leica, Wetzlar,
Germany) and the R&D mouse cell and tissue DAB
staining kit and counterstained with Hematoxylin. A
murine IgG1 isotype control antibody (Clone 11711,
R&D systems MAB002) was used as a negative experi-
mental control.
CD151 expression levels and subcellular localization
were examined in patient-derived and commercially
available tumor cell lines using the a-CD151 antibody
(Cat #NCL-CD151, Leica, Wetzlar, Germany). Alexa
fluor- 548 goat anti-mouse secondary (Cat #A21137,
Invitrogen, Carlsbad, California) was used and nuclear
counterstaining was performed with Vectashield mount-
ing medium for fluorescence with Dapi (Cat #H1200,
Vector Laboratories, Burlingame, California).
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Cell Culture
Ascites fluid was centrifuged for 10 minutes at low
speed at 4°C to pellet the cellular fraction. Cells were
resuspended in DMEM containing 10% FBS and Penicil-
lin-Streptomycin and allowed to adhere. Media was
changed daily until cells reached confluence at which
time they were passaged. RNA and immunostaining pro-
cedures were performed using only 2nd or 3rd passage
cells.
SiRNA Transfection
SMARTPool siRNA targeting human CD151 (Dharma-
con, Lafayette, Colorado) was transfected into SKOV3
or OVCAR5 cells using Lipofectamine as described pre-
viously [22]. Knockdown was confirmed at the RNA
level using qRT-PCR and at the protein level using IHC
as described above.
Migration and Invasion Assays
Migration and invasion experiments were performed
according to the manufacturer’s recommended protocol
(BD Biosciences, Franklin Lakes, New Jersey). Briefly,
S K O V 3o rO V C A R 5c e l l sw e r er e s u s p e n d e di ns e r u m
free media with or without mouse a-CD151 or control
mouse a-V5 antibody (Invitrogen, Carlsbad, California)
in the upper chamber of modified Boyden chamber
transwells. Bottom chambers were filled with media
containing 10% FBS as a chemoattractant. Cells were
allowed to migrate or invade through matrigel for 24
hours followed by calcein dye staining and visualization
using a fluorescent detector. Results shown are the
averages of 3 separate experiments performed in tripli-
cate. Statistical significance was measured using the Stu-
dent’s T test with p < 0.05 considered significant.
Results
CD151 is expressed across all stages of EOC
A total of 16 papillary serous epithelial ovarian tumors,
representing early- and late-stage disease and metastatic
nodules and recurrences, and two borderline ovarian
tumors were selected for RNA-Seq in our “discovery
set” of samples. Data for ~10,000 transcripts with an
average expression coverage level greater than one
across all samples was achieved. Coverage is a represen-
tation of the number of sequence reads mapping to the
exonic regions of a gene adjusted for the overall tran-
script length. Our search for candidates was defined by:
1) representation in all samples, 2) high transcript abun-
dance (top 5%), 3) lack of previous identification in
EOC, and 4) potential functionality as a treatment tar-
get. Based on these search criteria, CD151 became a
high-ranking candidate including the fact that it ranked
as high as the top 2% of genes expressed in our samples
(Table 1). The ability of CD151 to affect cell dissociation
and migration in other tumor models and our novel dis-
covery of its expression in EOC made CD151 a good
proof-of-principle candidate for further study.
To confirm these RNA-Seq results, we analyzed
CD151 expression using quantitative real-time RT-PCR
(qRT-PCR) in each of the discovery set of tumors that
had been sequenced (Table 2). In addition to these 18
samples, 25 additional papillary serous tumors, not
used for RNA-Seq, were then analyzed as a “validation
set”. While RNA-Seq expression levels and the qRT-
PCR-measured expression levels did not always correlate
precisely, all tumors expressed CD151 in readily detect-
able amounts. One explanation for the variation may be
that the real-time values are normalized to B2M and
GAPDH, whose expression may vary between tumor
samples [23]. In fact, in our RNA- Seq sample set, the
B2M and GAPDH transcript levels also varied markedly.
B2M coverage levels ranged greater than 30 fold
between samples and GAPDH levels ranged greater
than 10 fold (data not shown).
Overall, CD151 was expressed across all stages and no
differences were noted with either increasing stage or a
particular subtype (Table 1). One trend of note, given
the relatively small sample set in this study, was that
primary tumors, regardless of stage, on average
expressed higher levels of CD151 than either recurrent
tumors or metastatic lesions presenting at time of pri-
mary debulking surgery (27.4 v 18.4, respectively, p =
0.11). Borderline tumors possessed the lowest average
coverage values (14.0).
CD151 is expressed in EOC tumors and normal ovary
surface epithelial cells
Having identified overexpression on the RNA level, we
next evaluated the expression of CD151 protein in
tumors and normal ovary tissues using immunohisto-
chemistry. Previous reports revealed that CD151 loca-
lizes to either the cell membrane or within the
cytoplasm of cells in a context specific manner
[9,24-26]. Similar to both breast and colorectal cancers
[10,12,27-29], CD151 staining in ovarian tumors was
seen to be both membranous and cytoplasmic (Figure
1). CD151 was also present in normal ovarian surface
Table 1 RNA-Seq tumor coverage values
Disease Group Mean Range N#
Borderline 13.993 8.170-19.815 2
Early EOC 34.820 22.525-48.960 3
Late EOC 24.888 14.280-51.035 9
Metastatic 15.375 10.740-20.010 2
Recurrent 21.418 14.340-28.495 2
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membrane (Figure 1).
CD151 is expressed in ascites-derived and EOC cell lines
and immortalized ovarian surface epithelial cells (IOSE)
and is localized to cell-cell junctions
The known role of CD151 in cell-cell attachment and its
potential role in invasion/migration in ovarian cancer
led us next to examine the expression of CD151 in ovar-
ian-derived cell lines. These included ascites-derived
lines that we had established from patients with ovarian
cancer, commercially available EOC cell lines (A2780,
OVCAR3, OVCAR5 and SKOV3), and a number of
immortalized ovarian surface epithelial cell lines (IOSE,
IOSE397 and IOSE527). Quantitative RT-PCR revealed
that all ascites-derived cell lines and ovarian cancer cells
expressed CD151 message (Figure 2). In accord with our
finding that ovarian surface epithelial cells express
CD151 (Figure 1), IOSE also express CD151. The estab-
lished ovarian cell lines expressed similar levels of
CD151 compared to the primary ascites-derived lines
and the immortalized OSE lines (Figure 2).
Table 2 qRT-PCR tumor expression values
———Discovery—— ————Validation———
Disease Group Mean Range N# Mean Range N#
Borderline 0.038 0.019-0.056 2 - - -
Early EOC 0.257 0.046-0.495 3 0.050 0.014-0.090 6
Late EOC 0.404 0.003-2.45 9 1.022 0.085-3.410 7
Metastatic 0.708 0.497-0.920 2 1.160 0.039-1.231 8
Recurrent 0.122 0.005-0.239 2 0.365 0.031-3.605 4
Figure 1 CD151 is expressed in EOC tumors and normal ovary surface epithelial cells. a-d) Membranous (arrows) and cytoplasmic
(arrowheads) CD151 staining in early stage epithelial ovarian cancer. e-f) Primarily membranous (arrows) staining in the ovarian surface epithelial
cell layer of a normal ovary. Insets in a) and e) show higher magnification and staining detail. Insets show higher maginifcation images.
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ovarian ascites cell lines and EOC and IOSE cell lines
revealed that all patient-derived cell lines expressed
CD151 at the protein level (Figure 3). Furthermore,
CD151 localized not only to the cell membrane but
intriguingly was also expressed at very high concentra-
tions at cell-cell attachment points and cell membrane
extensions between cells (Figure 3). We are unaware of
this association being previously described in EOC
derived cell lines, although it has been reported pre-
viously in breast and epidermal carcinoma cell lines
[12,16,30,31]. Nonetheless, this is in agreement with the
postulated role of CD151 in mediating cell attachment
and migration.
Figure 2 CD151 qRT-PCR mRNA expression levels in patient-derived ascites cell lines. Patient-derived ascites cell lines, immortalized OSE,
and EOC cell lines express CD151.
Figure 3 Ascites cells and EOC cell lines express CD151 in vitro. CD151 localizes to the cell membrane with specificlocalization to cell-cell
junctions (white arrowheads) and cell membrane extensions (white arrows) in IOSE397 (a), IOSE527 (b), A2780 (c), OVCAR3 (d), OVCAR5 (e), and
SKOV3 (f) and patient derived cells 50A (g) and 54A (h). Original magnification 60X.
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blocked by inhibition of CD151
The postulated role of CD151 in cell migration and
tumor spread led us to test if blocking CD151 expres-
sion or function could inhibit ovarian cell migration and
invasion. Therefore, for these experiments we used
either siRNA- mediated knockdown or a specific CD151
antibody. We chose the SKOV3 (lower expression) and
OVCAR5 (higher expression) cell lines for their differen-
tial RNA expression of CD151 (Figure 2). Using a pool
of siRNA oligonucleotides targeting CD151, titration
experiments revealed optimal knockdown of CD151
mRNA (90% knockdown) andp r o t e i no c c u r r e d9 6
hours after transfection (Figure 4a-c). Both invasion and
migration of siCD151- transfected SKOV3 cells over 24
hours were significantly reduced following inhibition of
CD151 (Figure 4d-e). We also tested the inhibition of
invasion and migration in the higher expressing
OVCAR5 cell line. While siRNA- mediated inhibition of
CD151 in OVCAR5 cells significantly reduced their
migration, we found no evidence of an effect on inva-
sion (Figure 4d-e).
A second method of CD151 inhibition, antibody-
mediated, also significantly inhibited the ability of
SKOV3 cells to invade and migrate (Figure 4d-e). In the
CD151 higher expressing OVCAR5 cells, antibody-
mediated blockade, at the concentrations used, had only
an ~ 20% decrease in invasion but no measurable effect
on migration (Figure 4d-e).
Discussion
These studies are the first to demonstrate that the tetra-
spanin CD151 is expressed in epithelial ovarian cancers
and that its expression is independent of stage or histo-
logical subtype. We analyzed EOC tumor expression
levels of all RNA transcripts in an unbiased manner
Figure 4 Silencing and/or blocking of CD151 impedes SKOV3 and OVCAR5 migration and invasion. A-C) CD151 knockdown with siCD151
transfection at the mRNA (a) and protein (b-c) levels. d) Reduction of SKOV3 and OVCAR5 migration through transwell membranes in response
to either siCD151 transfection or aCD151 antibody treatment. e) Reduction of SKOV3 and OVCAR5 invasion through matrigel and transwell
membranes in response to either siCD151 transfection or treatment with aCD151 antibody. *p < 0.01. Results are representative of 3 separate
experiments performed in triplicate.
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possible novel therapeutic targ e t s .F r o mt h i sa n a l y s i so f
18 whole transcriptomes we identified high CD151
expression across all stages and subtypes of EOC,
including borderline ovarian tumors. We then con-
firmed expression of CD151 in this discovery set and a
second set of tumor tissues using qRT-PCR and immu-
nohistochemistry. The previously described role of
CD151 as a possible anti-metastatic target led us to
further examine the role of CD151 in ovarian cancer
and its migration and invasion in culture.
Immunohistochemical staining of EOC tumors and
normal ovary showed CD151 expression in tumor cells
as well as normal OSE cells. Immunocytochemistry of
c e l l sf r o mp a t i e n ta s c i t e sf l u i ds h o w e dC D 1 5 1t ob e
localized to the cell periphery and highly concentrated
at cell-cell junction points and along outstretched cellu-
lar elongations. Finally, functional studies showed that
SKOV3 and OVCAR5 cell invasion and migration are
differentially inhibited by a-CD151 antibody or siRNA-
mediated knockdown of CD151. It appears from these
experiments that the level of CD151 expression may
affect our ability to inhibit invasion and migration and
therefore CD151 blockade m a yn e e dt ob et i t r a t e dt o
achieve the most robust inhibition.
CD151 has previously been postulated to play impor-
tant roles in a number of cancers including colorectal
and breast cancers but no studies had previously identi-
fied or examined its expression and function in ovarian
cancer. In colorectal cancer CD151 is differentially
expressed between normal (high expression), primary
(low expression), and metastatic (high expression) tissue
[ 2 8 ] .I ti sp r o p o s e dt h a tt h e s ec h a n g e sa r ep a r to fa
hypoxic response that drives cell detachment and migra-
tion [28]. In our own discovery sample set of EOC
tumors, while not reaching statistical significance, we
did find an interesting trend of higher CD151 expression
in primary ovarian tumors and relatively lower expres-
sion in disseminated metastatic or recurrent disease
(Tables 1 and 2). It is possible that this is due to differ-
ent environmental effects in secondary sites, such as
hypoxia or surrounding cell types. This hypothesis will
need to be expanded upon by examination of a larger
collection of samples.
The expression of tetraspanin CD151 on the cell sur-
face of EOC cells may play a role in the spread of these
cells to other organs in the peritoneal cavity. In xeno-
graft tumor models, antibody-mediated inhibition of
CD151 has been shown to hinder the spread of meta-
static tumors, reinforcing the idea that CD151 is func-
tionally important for either cell detachment from a
tumor or migration away from that tumor [19,32]. Intri-
guingly, in breast cancer models comparing CD151-
expressing cells against CD151-ablated cells, tumor
growth was delayed in the absense of CD151 [12]. In
immunohistochemical studies of breast cancer, staining
varied greatly in both intensity and cellular localization,
which may reflect the heterogeneity of the tumor cells’
environment or activity [33]. CD151 staining intensity
and localization in normal OSE and ovarian tumor cells
also varies. CD151 protein was localized to both the
membrane and the cytoplasm of cancer cells (Figure 1).
In contrast, in normal ovarian surface CD151 localized
mostly to the cell membrane. It is possible that the
internalization of CD151 into cytoplasmic endosomes
may reduce its ability to cooperate with other binding
partners and cells, allowing detachment from the pri-
mary tumor [25]. On ascites-derived patient cell lines,
IOSE, and EOC cell lines, CD151 not only localized to
the membrane but more specifically to the cell-cell junc-
tions and along cell membrane extensions (Figure 3).
Although in vitro cellular localization suggests no differ-
ence between cancerous cell lines and OSE cells, this
may due to distinct conditions in cell culture such as
attachment to plastic and tightly controlled O2/CO2
balance.
Expression of CD151 in EOC tumors, the known
involvement of CD151 in cell migration and invasion,
and the in vivo ability of aCD151 antibody to contain
breast cancer tumors to single nodules and eliminate
tumor spread suggested that CD151 may also represent
a promising and relevant candidate for therapeutic tar-
geting in ovarian cancer. We show that in the ovarian
cancer cell lines SKOV3 and OVCAR5, CD151 is a
functionally important molecule whose silencing or
blockade impeded cell migration or invasion to different
levels dependent on level of CD151 expression. A role
for CD151 in cell migration and invasion is consistent
through many cancer types including breast, prostate,
colorectal, and pancreatic cancers [15,19,32,34-36]. Ulti-
mately, the value of CD151 as a therapeutic target in
EOC will need to be demonstrated in in vivo studies.
Abbreviations
EOC: epithelial ovarian cancer; RIN: RNA integrity number; IOSE: immortalized
ovarian surface epithelial.
Author details
1Department of Genetics and Genomic Sciences, Mount Sinai School of
Medicine, New York, NY, USA.
2Department of Pathology, Mount Sinai
School of Medicine, New York, NY, USA.
3Division of Gynecologic Oncology,
Mount Sinai School of Medicine, New York, NY, USA.
4San Gerardo Hospital,
University of Milano-Bicocca, Monza, Italy.
5Department of Oncology,
Instituto “Mario Negri”, Milano, Italy.
6Mario Negri Gynecological Oncology
Group (MaNGO), Milano, Italy.
Authors’ contributions
RAM participated in sample collection, selection, sequencing analysis, and all
molecular studies and manuscript drafting. LL participated in all molecular
studies. ES participated in sample collection and sequencing analysis. HS
provided bioinformatics support and analysis. FH participated in sample
collection and cell-line derivation. PS provided pathological staging and
Mosig et al. Journal of Ovarian Research 2012, 5:4
http://www.ovarianresearch.com/content/5/1/4
Page 7 of 9staining analysis. SC supplied samples and clinical information. RF, SM, and
MD supplied samples and clinical information and participated in study
design. RS provided bioinformatics support and analysis as well as data
interpretation. PD supplied samples and clinical information and participated
in study design. JAM participated in overall study design, sample selection,
sequencing analysis, and preparation of the manuscript. All Authors
reviewed and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 November 2011 Accepted: 24 January 2012
Published: 24 January 2012
References
1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W,
Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR,
Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK: SEER Cancer
Statistics Review, 1975-2007 [Internet] Bethesda, MD: National Cancer
Institute.
2. Cannistra SA: Cancer of the ovary. N Engl J Med 2004, 351:2519-29.
3. Guarneri V, Piacentini F, Barbieri E, Conte PF: Achievements and unmet
needs in the management of advanced ovarian cancer. Gynecol Oncol
2010, 117:152-8.
4. Pleasance ED, Stephens PJ, O’Meara S, McBride DJ, Meynert A, Jones D,
Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR,
Ordonez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M,
Leroy C, Marshall J, Menzies A, Butler A, Teague JW, Mangion J, Sun YA,
McLaughlin SF, Peckham HE, Tsung EF, Costa GL, Lee CC, Minna JD,
Gazdar A, Birney E, Rhodes MD, McKernan KJ, Stratton MR, Futreal PA,
Campbell PJ: A small-cell lung cancer genome with complex signatures
of tobacco exposure. Nature 2010, 463:184-90.
5. Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST,
Wunderlich A, Barmeyer C, Seemann P, Koenig J, Lappe M, Kuss AW,
Garshasbi M, Bertram L, Trappe K, Werber M, Herrmann BG, Zatloukal K,
Lehrach H, Schweiger MR: Somatic mutation profiles of MSI and MSS
colorectal cancer identified by whole exome next generation
sequencing and bioinformatics analysis. PLoS One 2010, 5:e15661.
6. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ,
Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J,
Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-
Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T,
Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z,
Royce T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L,
Teague J, Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR,
Futreal PA, Stratton MR: A comprehensive catalogue of somatic
mutations from a human cancer genome. Nature 2010, 463:191-6.
7. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM,
Buck G, Chen L, Beare D, Latimer C, Widaa S, Hinton J, Fahey C, Fu B,
Swamy S, Dalgliesh GL, Teh BT, Deloukas P, Yang F, Campbell PJ,
Futreal PA, Stratton MR: Signatures of mutation and selection in the
cancer genome. Nature 2010, 463:893-8.
8. Hasegawa M, Furuya M, Kasuya Y, Nishiyama M, Sugiura T, Nikaido T,
Momota Y, Ichinose M, Kimura S: CD151 dynamics in carcinoma-stroma
interaction: Integrin expression, adhesion strength and proteolytic
activity. Lab Invest 2007, 87:882-92.
9. Liu L, He B, Liu WM, Zhou D, Cox JV, Zhang XA: Tetraspanin CD151
promotes cell migration by regulating integrin trafficking. J Biol Chem
2007, 282:31631-42.
10. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, Hemler ME: Disruption of
laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast
cancer cells to ErbB2 antagonists. Cancer Res 2010, 70:2256-63.
11. Zuo H, Liu Z, Liu X, Yang J, Liu T, Wen S, Zhang XA, Cianflone K, Wang D:
CD151 gene delivery after myocardial infarction promotes functional
neovascularization and activates FAK signaling. Mol Med 2009, 15:307-15.
12. Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR,
Andzelm MM, Strominger JL, Brown M, Hemler ME: CD151 accelerates
breast cancer by regulating alpha 6 integrin function, signaling, and
molecular organization. Cancer Res 2008, 68:3204-13.
13. Sawada S, Yoshimoto M, Odintsova E, Hotchin NA, Berditchevski F: The
tetraspanin CD151 functions as a negative regulator in the adhesion-
dependent activation of ras. J Biol Chem 2003, 278:26323-6.
14. Franco M, Muratori C, Corso S, Tenaglia E, Bertotti A, Capparuccia L,
Trusolino L, Comoglio PM, Tamagnone L: The tetraspanin CD151 is
required for met-dependent signaling and tumor cell growth. J Biol
Chem 2010.
15. Zhu GH, Huang C, Qiu ZJ, Liu J, Zhang ZH, Zhao N, Feng ZZ, Lv XH:
Expression and prognostic significance of CD151, c-met, and integrin
alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci 2010.
16. Johnson JL, Winterwood N, DeMali KA, Stipp CS: Tetraspanin CD151
regulates RhoA activation and the dynamic stability of carcinoma cell-
cell contacts. J Cell Sci 2009, 122:2263-73.
17. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ,
Wu JC, Bai DS, Li JC, Liu KD, Fan J: Role of overexpression of CD151 and/
or c-met in predicting prognosis of hepatocellular carcinoma. Hepatology
2009, 49:491-503.
18. Yamada M, Sumida Y, Fujibayashi A, Fukaguchi K, Sanzen N, Nishiuchi R,
Sekiguchi K: The tetraspanin CD151 regulates cell morphology and
intracellular signaling on laminin-511. FEBS J 2008, 275:3335-51.
19. Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP: The inhibition of
tumor cell intravasation and subsequent metastasis via regulation of in
vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 2008,
13:221-34.
20. Marchini S, Mariani P, Chiorino G, Marrazzo E, Bonomi R, Fruscio R, Clivio L,
Garbi A, Torri V, Cinquini M, Dell’Anna T, Apolone G, Broggini M,
D’Incalci M: Analysis of gene expression in early-stage ovarian cancer.
Clin Cancer Res 2008, 14:7850-60.
21. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: Mapping and
quantifying mammalian transcriptomes by RNA-seq. Nat Methods 2008,
5:621-8.
22. Mosig RA, Dowling O, Difeo A, Ramirez MC, Parker IC, Abe E, Diouri J,
Aqeel AA, Wylie JD, Oblander SA, Madri J, Bianco P, Apte SS, Zaidi M,
Doty SB, Majeska RJ, Schaffler MB, Martignetti JA: Loss of MMP-2 disrupts
skeletal and craniofacial development and results in decreased bone
mineralization, joint erosion and defects in osteoblast and osteoclast
growth. Hum Mol Genet 2007, 16:1113-23.
23. Tricarico C, Pinzani P, Bianchi S, Paglierani M, Distante V, Pazzagli M,
Bustin SA, Orlando C: Quantitative real-time reverse transcription
polymerase chain reaction: Normalization to rRNA or single
housekeeping genes is inappropriate for human tissue biopsies. Anal
Biochem 2002, 309:293-300.
24. Lineberry N, Su L, Soares L, Fathman CG: The single subunit
transmembrane E3 ligase gene related to anergy in lymphocytes
(GRAIL) captures and then ubiquitinates transmembrane proteins across
the cell membrane. J Biol Chem 2008, 283:28497-505.
25. Rana S, Claas C, Kretz CC, Zoeller M: Activation-induced internalization
differs for the tetraspanins CD9 and Tspan8: Impact on tumor cell
motility. Int J Biochem Cell Biol 2010.
26. Yang X, Claas C, Kraeft SK, Chen LB, Wang Z, Kreidberg JA, Hemler ME:
Palmitoylation of tetraspanin proteins: Modulation of CD151 lateral
interactions, subcellular distribution, and integrin-dependent cell
morphology. Mol Biol Cell 2002, 13:767-81.
27. Klosek SK, Nakashiro K, Hara S, Goda H, Hasegawa H, Hamakawa H: CD151
regulates HGF-stimulated morphogenesis of human breast cancer cells.
Biochem Biophys Res Commun 2009, 379:1097-100.
28. Chien CW, Lin SC, Lai YY, Lin BW, Lin SC, Lee JC, Tsai SJ: Regulation of
CD151 by hypoxia controls cell adhesion and metastasis in colorectal
cancer. Clin Cancer Res 2008, 14:8043-51.
29. Sauer G, Kurzeder C, Grundmann R, Kreienberg R, Zeillinger R, Deissler H:
Expression of tetraspanin adaptor proteins below defined threshold
values is associated with in vitro invasiveness of mammary carcinoma
cells. Oncol Rep 2003, 10:405-10.
30. Sharma C, Yang XH, Hemler ME: DHHC2 affects palmitoylation, stability,
and functions of tetraspanins CD9 and CD151. Mol Biol Cell 2008,
19:3415-25.
31. Shigeta M, Sanzen N, Ozawa M, Gu J, Hasegawa H, Sekiguchi K: CD151
regulates epithelial cell-cell adhesion through PKC- and Cdc42-
dependent actin cytoskeletal reorganization. J Cell Biol 2003, 163:165-76.
32. Testa JE, Brooks PC, Lin JM, Quigley JP: Eukaryotic expression cloning with
an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/
Mosig et al. Journal of Ovarian Research 2012, 5:4
http://www.ovarianresearch.com/content/5/1/4
Page 8 of 9CD151) as an effector of human tumor cell migration and metastasis.
Cancer Res 1999, 59:3812-20.
33. Sadej R, Romanska H, Baldwin G, Gkirtzimanaki K, Novitskaya V, Filer AD,
Krcova Z, Kusinska R, Ehrmann J, Buckley CD, Kordek R, Potemski P,
Eliopoulos AG, Lalani e, Berditchevski F: CD151 regulates tumorigenesis by
modulating the communication between tumor cells and endothelium.
Mol Cancer Res 2009, 7:787-98.
34. Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-
Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Zoller M:
Colocalization of the tetraspanins, CO-029 and CD151, with integrins in
human pancreatic adenocarcinoma: Impact on cell motility. Clin Cancer
Res 2005, 11:2840-52.
35. Funakoshi T, Tachibana I, Hoshida Y, Kimura H, Takeda Y, Kijima T,
Nishino K, Goto H, Yoneda T, Kumagai T, Osaki T, Hayashi S, Aozasa K,
Kawase I: Expression of tetraspanins in human lung cancer cells:
Frequent downregulation of CD9 and its contribution to cell motility in
small cell lung cancer. Oncogene 2003, 22:674-87.
36. Tokuhara T, Hasegawa H, Hattori N, Ishida H, Taki T, Tachibana S, Sasaki S,
Miyake M: Clinical significance of CD151 gene expression in non-small
cell lung cancer. Clin Cancer Res 2001, 7:4109-14.
doi:10.1186/1757-2215-5-4
Cite this article as: Mosig et al.: Application of RNA-Seq transcriptome
analysis: CD151 is an Invasion/Migration target in all stages of epithelial
ovarian cancer. Journal of Ovarian Research 2012 5:4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mosig et al. Journal of Ovarian Research 2012, 5:4
http://www.ovarianresearch.com/content/5/1/4
Page 9 of 9